TX-1123

A cell-permeable, reversible and substrate-competitive arylidene-cyclopentenedione derived tyrphostin that acts as a kinase inhibitor for Src, eEF2-K, and PKA (IC₅₀ = 2.2, 3.2, and 9.6 µM, respectively). Inhibits EGFR-K and PKC only at much higher concentrations (IC₅₀ = 320 µM). Reported to exhibit potent anti-tumor activity (EC₅₀ = 3.66 and 39 µM in HepG2 and HCT116 tumor cells, respectively) with greatly reduced mitochondrial- (≥1000-fold) and hepato-toxicity (≥50-fold) when compared with another tyrphostin, AG 17 (Cat. No. 658425). May be useful as a therapeutic agent for cancer treatment in animal models.

A cell-permeable, reversible, and substrate-competitive arylidene-cyclopentenedione derived tyrphostin that acts as an inhibitor for Src, eEF2-K, and PKA (IC₅₀ = 2.2, 3.2, and 9.6 µM, respectively), while it inhibits EGFR-K and PKC at much higher concentrations (IC₅₀ = 320 µM). Displays potent antitumor activity (EC₅₀ = 3.66 and 39 µM in HepG2 and HCT116 tumor cells, respectively) with greatly reduced mitochondrial- (≥1000-fold) and hepato-toxicity (≥50-fold) when compared with another tyrphostin, AG 17 (Cat. No. 658425). It is therefore a more promising candidate as a therapeutic agent for cancer treatment.

Cell permeable: yes

Primary Target
Src

Product competes with ATP.

Reversible: yes

Target IC₅₀: 2.2, 3.2, and 9.6 µM against Src, eEF2-K, and PKA, respectively

Packaged under inert gas

Following reconstitution, aliquot and freeze (- 20°C). Stock solutions are stable for up to 3 months at -20°C.

Hori, H., et al. 2003. Cell. Mol. Biol. Lett.8, 528.
Hori, H., et al. 2002. Bioorg. Med. Chem.10, 3257.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Toxicity: Harmful (C)